Medical News

RSS

Food labels can help in making heart-healthy food choices

February is American Heart Month -- and a good time to make simple changes in your diet to reduce your risk for heart disease.

30 Jan 2010

Today's opinions and editorials

By not acknowledging America's concerns about health reform Wednesday night, the president appeared inflexible and incapable of real compromise (Dr. Marc Siegel, 1/28).

30 Jan 2010

Salient Pharmaceuticals receives TETF commercialization award for CASAD therapy commercialization

Houston Technology Center (HTC), announced today that client company Salient Pharmaceuticals received a $2 million commercialization award from the Texas Emerging Technology Fund (TETF) for the commercialization of their CASAD therapy, an all natural product used to prevent and treat some cancer therapy-induced side effects.

29 Jan 2010

Joslin.org and dLife.com announce new online partnership

Joslin.org, the Internet site for Harvard-affiliated Joslin Diabetes Center, the world's preeminent diabetes research and clinical care organization, and dLife.com, the leading online community for people living with diabetes, today announced a new online partnership.

29 Jan 2010

Diffusion Pharmaceuticals closes on $5.9M in additional private financing

Diffusion Pharmaceuticals LLC, a clinical-stage drug-development company commercializing first-in-class drugs to treat serious or life-threatening unmet medical conditions, today announced that it closed on $5.9 million in additional private financing during the second half of 2009, bringing the total the company raised in 2009 to $7.1 million.

29 Jan 2010

Positive Phase 2 trial results of Keryx Biopharmaceuticals' KRX-0401 announced

Keryx Biopharmaceuticals, Inc. (the "Company") today announced that an article entitled "Clinical and Translational Studies of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia," reporting Phase 2 data demonstrating the single agent activity of KRX-0401 (Perifosine) for the treatment of advanced Waldenstrom's Macroglobulinemia ("Waldenstrom's"), will appear in the February 1, 2010 issue of Clinical Cancer Research.

29 Jan 2010

Recent releases in Global Health

Rajiv Shah's appointment as USAID administrator "comes at a crucial time of challenge and opportunity for the Agency to improve the nutritional well-being of impoverished societies," write the authors of a Lancet Comment that examines the U.S. Global Hunger and Food Security Initiative. Though the initiative "sends a clear message to the world about U.S. intent to partner with poor nations to achieve their national food and nutrition goals … the Initiative's nutrition plan, unlike its detailed agricultural blueprint, currently lacks a comprehensive set of aims, activities, research needs, and programme benchmarks," the authors write.

29 Jan 2010

Derma Sciences implements reverse stock split for trading on NASDAQ Stock Market

Derma Sciences, Inc., a specialty medical device/pharmaceutical company focused on advanced wound care, today announced that it would implement an 8-for-1 reverse split of its issued and outstanding common shares, effective for shareholders of record on February 1, 2010, and a proportional reduction of its authorized common and preferred shares.

29 Jan 2010

ID Watchdog, Amacore Group announce multi-faceted marketing agreement

ID Watchdog, Inc., provider of the most comprehensive identity theft protection and resolution services in the market today, announced a multi-faceted marketing agreement with the Amacore Group, Inc.

29 Jan 2010

New mathematical model helps in predicting treatment outcomes for cervical cancer patients

Cervical cancer is highly curable when caught early. But in a third of cases, the tumor responds poorly to therapy or recurs later, when cure is much less likely.

29 Jan 2010

GlaxoSmithKline's Lamictal XR Extended-Release Tablets receive FDA approval

laxoSmithKline announced today that the U.S. Food and Drug Administration has approved Lamictal®XR™ (lamotrigine) Extended-Release Tablets as once-a-day, add-on therapy for epilepsy in patients ages 13 years and older with primary generalized tonic-clonic seizures.

29 Jan 2010

Health bill - 'on life support' - continues to highlight political divides

President Obama's State of the Union speech has so far failed to unite Democrats on a health reform strategy as they "stared down a political nightmare," The Associated Press reports.

29 Jan 2010

ConjuChem Biotechnologies reports financial results for fiscal year ended October 31, 2009

The Company's net loss for the quarter ended October 31, 2009 amounted to $2.5 million or ($0.01) per share, compared to $10.9 million or ($0.04) per share, for the quarter ended October 31, 2008.

29 Jan 2010

Acceleware grants stock options to acquire 1,355,000 common shares

Acceleware® Corp. (the "Corporation") a leading developer of high performance computing applications, today announced that it has granted stock options to acquire up to 1,355,000 common shares of the Corporation to certain of its employees, officers and directors.

29 Jan 2010

Democrats offer varying views on health overhaul's fate

NPR interviewed House Energy and Commerce Committee Chairman Henry Waxman, D-Calif., to get his reactions to the President's Wednesday night speech.

29 Jan 2010

Agent-enhanced CT scan plays a supporting role in diagnosing severe cases of H1N1 flu virus

Published reports on the usefulness of CT scans for complicated H1N1 cases have spurred use of these procedures in U.S. hospitals. According to healthcare market research publisher Kalorama Information, this opens up a pathway of diagnostics for physicians and overall is a positive sign not only for the technology but also for companies making chemical agents for procedures.

29 Jan 2010

FDA grants accelerated approval for GlaxoSmithKline's TYKERB

GlaxoSmithKline (NYSE: GSK) announced today that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for a new combination regimen using TYKERB® (lapatinib) as a first-line, all-oral treatment for women with metastatic breast cancer.

29 Jan 2010